Skip Navigation

European Heart Journal 2001 22(17):1572-1577; doi:10.1053/euhj.2000.2554
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Monaco, C.
Right arrow Articles by Maseri, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monaco, C.
Right arrow Articles by Maseri, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Autoantibodies against oxidized low density lipoproteins in patients with stable angina, unstable angina or peripheral vascular disease; pathophysiological implications

C. Monacoa, F. Creaa,f1, G. Niccolia, F. Summariaa, D. Cianflonea, R. Bordoneb, G. Bellomob and A. Maseria

a Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Rome, Italy
b Dipartimento di Scienze Mediche, Università di Torino, Novara, Italy

revised November 27, 2000; accepted November 29, 2000

Abstract

Background Antibody antioxidized low density lipoproteins (oxLDL) might play a role both in atherogenesis and in the pathogenesis of acute coronary syndromes.

Methods and Results Antibody titres to oxLDL and levels of C-reactive protein were compared in unstable angina, stable angina or peripheral artery disease. Antibody titres to LDL oxidated by CuSO4for 2, 4 and 18h (Cu-oxLDL-Ab2-4-18) or by peroxidase (HRP-oxLDL-Ab) were assessed by ELISA. Cu-oxLDL-Ab2-4-18were consistently higher in peripheral artery disease than in unstable angina (P<0·001, P<0·001, P=0·01, respectively) or in stable angina (P<0·001, P=0·01, P=ns) but similar in unstable and stable angina. Accordingly, HRP-oxLDL-Ab were higher in peripheral artery disease than in unstable angina (P<0·001) or stable angina (P=0·04) but similar in unstable and stable angina. The number of arterial stenoses was higher in peripheral artery disease than unstable and stable angina (P<0·01). Cu-oxLDL-Ab and HRP-oxLDL-Ab correlated with the severity of atherosclerosis (P<0·01, R=0·4;P=0·02, R=0·3 respectively). Conversely, C-reactive protein levels were higher in unstable than in stable angina (P<0·001) or in peripheral artery disease (P<0·03) but similar in stable angina and peripheral artery disease and did not correlate with the severity of atherosclerosis.

Conclusion The autoimmune response to oxLDL is likely to play an important role in atherogenesis but not in precipitating acute coronary syndromes.

Key Words: Lipoproteins, antibodies, inflammation, coronary artery disease, peripheral artery disease

f1 Correspondence: Prof. Filippo Crea, Istituto di Cardiologia, Università Cattolica del Sacro Cuore, L.go A. Gemelli, 8, 00168 Rome, Italy.

References

  1. Mazzone A, De Servi S, Ricevuti G. Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation. 1993;88:358–363[Abstract/Free Full Text]
  2. Moreno PR, Bernardi VH, Lopez-Cuellar J. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation. 1996;94:3090–3097[Abstract/Free Full Text]
  3. Dinerman JL, Mehta JL, Saldeen TG. Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction. J Am Coll Cardiol. 1990;15:1559–1563[Abstract]
  4. Biasucci LM, D'Onofrio G, Liuzzo G. Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. J Am Coll Cardiol. 1996;27:611–616[Abstract]
  5. Neri Serneri GG, Prisco D, Martini F. Acute T-cell activation is detectable in unstable angina. Circulation. 1997;95:1806–1812[Abstract/Free Full Text]
  6. Van der Wal AC, Piek JJ, de Boer OJ. Recent activation of the plaque immune response in coronary lesions underlying acute coronary syndromes. Heart. 1998;80:14–18[Abstract/Free Full Text]
  7. Van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36–44[Abstract/Free Full Text]
  8. Liuzzo G, Biasucci LM, Rebuzzi AG. Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation. 1996;94:2373–2380[Abstract/Free Full Text]
  9. Liuzzo G, Buffon A, Biasucci LM. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation. 1998;98:2370–2376[Abstract/Free Full Text]
  10. Biasucci LM, Liuzzo G, Caligiuri G. Episodic activation of the coagulation system in unstable angina does not elicit an acute phase reaction. Am J Cardiol. 1996;77:85–87[CrossRef][ISI][Medline]
  11. Kol A, Sperti G, Shani J. Cytomegalovirus replication is not a cause of instability in unstable angina. Circulation. 1995;91:1910–1913[Abstract/Free Full Text]
  12. Pasceri V, Cammarota G, Patti G. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation. 1998;97:1675–1679[Abstract/Free Full Text]
  13. Gupta S, Leatham EW, Carrington D, Mendall MA, Kasji JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404–407[Abstract/Free Full Text]
  14. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet. 1997;350:404–407[CrossRef][ISI][Medline]
  15. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J. 1999;20:121–127[Abstract/Free Full Text]
  16. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 1998;98:1487–1494[Abstract/Free Full Text]
  17. Salonen JT, Yla-Herttuala S, Yamamoto R. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883–887[CrossRef][ISI][Medline]
  18. Maggi E, Finardi G, Poli M. Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk. Coron Artery Dis. 1993;4:1119–1122[ISI][Medline]
  19. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci USA. 1981;78:6499–6503[Abstract/Free Full Text]
  20. Diaz MN, Frei B, Vita JA, Keany JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med. 1997;337:408–416[Free Full Text]
  21. Boyd HC, Gown AM, Wolfbauer G, Chait A. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am J Pathol. 1989;135:815–825[Abstract]
  22. Palinski W, Rosenfeld ME, Yla-Herttuala S. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A. 1989;86:1372–1376[Abstract/Free Full Text]
  23. Yla-Herttuala S, Palinski W, Rosenfeld ME. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086–1095[ISI][Medline]
  24. Hoff HF, O'Neil J. Lesion-derived low density lipoprotein and oxidized low density lipoprotein share a lability for aggregation, leading to enhanced macrophage degradation. Arterioscler Thromb. 1991;11:1209–1222[Abstract/Free Full Text]
  25. Harduin P, Tailleux A, Lestavel S, Clavey V, Fruchart JC, Fievet C. Immunological and functional properties of in vitro oxidized low density lipoprotein. J Lipid Res. 1995;36:919–930[Abstract]
  26. Maggi E, Marchesi E, Ravetta V, Martignoni A, Finardi G, Bellomo G. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation. J Hypertens. 1995;13:129–138[ISI][Medline]
  27. Lehtimaki T, Lehtinen S, Solakivi T. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol. 1999;19:23–27[Abstract/Free Full Text]
  28. Bui MN, Sack MN, Moutsatsos G. Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. Am Heart J. 1996;131:663–667[CrossRef][ISI][Medline]
  29. Iribarren C, Folsom AR, Jacobs DR Jr., Gross MD, Belcher JD, Eckfeldt JH. Association of serum vitamin levels, LDL susceptibility to oxidation, and autoantibodies against MDA-LDL with carotid atherosclerosis. A case-control study. The ARIC Study Investigators. Atherosclerosis Risk in Communities. Arterioscler Thromb Vasc Biol. 1997;17:1171–1177[Abstract/Free Full Text]
  30. Bergmark C, Wu R, de Faire U, Lefvert AK, Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol. 1995;15:441–445[Abstract/Free Full Text]
  31. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1995;92:3893–3897[Abstract/Free Full Text]
  32. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A. 1988;85:2805–2809[Abstract/Free Full Text]
  33. Parhami F, Fang ZT, Fogelman AM, Andalibi A, Territo MC, Berliner JA. Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. J Clin Invest. 1993;92:471–478[ISI][Medline]
  34. Scott B, Liblau R, Degermann S. A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity. 1994;1:73–83[CrossRef][ISI][Medline]
  35. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA. 1995;92:821–825[Abstract/Free Full Text]
  36. Ameli S, Hultgardh-Nilsson A, Regnstrom J. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol. 1996;16:1074–1079[Abstract/Free Full Text]
  37. Tataru MC, Heinrich J, Junker R. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J. 2000;21:1000–1008[Abstract/Free Full Text]
  38. Maseri A. Inflammation, atherosclerosis and ischemic events—exploring the hidden side of the moon. N Engl J Med. 1997;336:1014–1016[Free Full Text]
  39. Monaco C, Rossi E, Milazzo D. Different thrombotic and inflammatory patterns between unstable angina and peripheral vascular disease (Abstr). J Am Coll Cardiol. 1998;31:488A

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
G. S. Ginsburg
Regression of Atherosclerosis With Therapeutic Antibodies: Pipe Cleaner or Pipe Dream?
J. Am. Coll. Cardiol., December 11, 2007; 50(24): 2319 - 2321.
[Full Text] [PDF]

Home page
 CirculationHome page
Y. Shoenfeld, R. Wu, L. D. Dearing, and E. Matsuura
Are Anti-Oxidized Low-Density Lipoprotein Antibodies Pathogenic or Protective?
Circulation, October 26, 2004; 110(17): 2552 - 2558.
[Full Text] [PDF]

Home page
 Vasc MedHome page
A. Silvestro, F. Scopacasa, A. Ruocco, G. Oliva, V. Schiano, C. Zincarelli, and G. Brevetti
Inflammatory status and endothelial function in asymptomatic and symptomatic peripheral arterial disease
Vascular Medicine, November 1, 2003; 8(4): 225 - 232.
[Abstract] [PDF]

Home page
 CVIHome page
G. Virella and M. F. Lopes-Virella
Lipoprotein Autoantibodies: Measurement and Significance
Clin. Vaccine Immunol., July 1, 2003; 10(4): 499 - 505.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
B. de Geest and D. Collen
Antibodies against oxidized LDL for non-invasive diagnosis of atherosclerotic vascular disease
Eur. Heart J., September 1, 2001; 22(17): 1517 - 1518.
[PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Monaco, C.
Right arrow Articles by Maseri, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monaco, C.
Right arrow Articles by Maseri, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?